Tau Biomarker Program

A highly differentiated and important part of the tau oligomer program is based on our discovery that the formation of certain tau oligomer structures endows tau to be cleaved at specific sites, causing irreversible loss of function and a higher propensity of the cleaved tau to aggregate and sequester normal tau protein, a gain of toxic function. The neo-epitopes (new antibody binding regions on an antigen) generated by tau oligomer cleavage were identified and used to develop novel antibodies as biomarkers that can resolve non-AD from AD specimens.

Using this approach, we are developing assays for patient recruitment and an efficacy marker for clinical studies.